C2 Pharma and Anklam Extrakt develop cannabidiol-based compounds

C2 Pharma will implement its cannabis strategy by collaborating with the European-based manufacturer of botanical extracts to provide pharmaceutical companies with a reliable supply of cannabis compounds

C2 Pharma and Anklam Extrakt announced at CPhI 2018, Madrid their R&D collaboration to develop GMP-compliant manufacture of cannabidiol CBD-based compounds.

C2 Pharma can be found at CPhI in Hall 6, Booth 6F40 and Anklam Extrakt in Hall 5, Booth 5G60. The collaboration between the companies covers various botanicals extracted from cannabis for pharmaceutical use.

The new R&D programme announced in the first phase include:

  • Cannabidiol (CBD) as an API
  • Cannabis oil
  • Cannabis extract

This collaboration supports C2 Pharma’s major initiative to bring a reliable source of naturally extracted GMP-compliant Cannabidiol (CBD) to the pharma industry, also reported by Manufacturing Chemist.

The initiative will leverage C2 Pharma’s established good agricultural practices (GAP) process, analytical know-how at its affiliate ASM Research Chemicals and logistics know-how at its affiliate Logistics4pharma.

It also supports Anklam Extrakt’s strategy to continue its expansion in the pharmaceutical sector and offer a broad range of GMP-compliant botanical extracts to the industry.

Initial samples are expected to be available in the first quarter of 2019.

“Our collaboration with Anklam Extrakt allows two expert companies to work together to deliver what the pharma industry needs: a reliable source of cannabisderived compounds and APIs for the long term,” said Andrew Badrot, CEO of C2 Pharma said.

“Drawing on the complementary expertise of our affiliates, we jointly cover the entire cannabis supply chain, from GAP cultivation, to GMP manufacturing, analytics, transportation and warehousing. It is a value proposition that is hard to beat.”

“We are delighted to work with C2 Pharma and to be able to contribute to their vision to build a reliable source of CBD-based compounds. They have the market access, regulatory knowledge and the energy to push this complex project through,” said Claudia Puhn, Managing Director of Anklam Extrakt.

“Combined with Anklam Extrakt’s manufacturing capabilities, compliance with German regulations and expertise in botanical extracts, this collaboration is bound to be successful.”

Featured Companies

C2 Pharma (more information, website)